Teacher Retirement System of Texas Acquires 4,701 Shares of Illumina, Inc. (NASDAQ:ILMN)

Teacher Retirement System of Texas increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 25.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 23,515 shares of the life sciences company’s stock after purchasing an additional 4,701 shares during the quarter. Teacher Retirement System of Texas’ holdings in Illumina were worth $9,538,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of ILMN. Geode Capital Management LLC increased its holdings in shares of Illumina by 5.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,539,352 shares of the life sciences company’s stock worth $1,198,406,000 after purchasing an additional 128,312 shares during the period. Polen Capital Management LLC lifted its position in shares of Illumina by 4.4% during the 2nd quarter. Polen Capital Management LLC now owns 2,480,776 shares of the life sciences company’s stock worth $1,173,928,000 after buying an additional 103,747 shares during the period. Nuveen Asset Management LLC lifted its holdings in shares of Illumina by 6.4% during the second quarter. Nuveen Asset Management LLC now owns 1,977,856 shares of the life sciences company’s stock valued at $935,941,000 after acquiring an additional 119,769 shares during the period. GUARDCAP ASSET MANAGEMENT Ltd boosted its position in Illumina by 16.1% in the second quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 1,227,165 shares of the life sciences company’s stock valued at $580,707,000 after buying an additional 169,934 shares in the last quarter. Finally, Ownership Capital B.V. boosted its holdings in shares of Illumina by 3.9% in the 3rd quarter. Ownership Capital B.V. now owns 1,063,540 shares of the life sciences company’s stock worth $431,382,000 after acquiring an additional 39,649 shares in the last quarter. Institutional investors and hedge funds own 84.89% of the company’s stock.

Several equities research analysts have recently commented on ILMN shares. Barclays raised Illumina from an “underweight” rating to an “equal weight” rating and lowered their target price for the company from $432.72 to $412.00 in a research note on Tuesday. SVB Leerink increased their target price on shares of Illumina from $420.00 to $430.00 and gave the stock a “market perform” rating in a report on Tuesday. Citigroup cut their price objective on Illumina from $450.00 to $400.00 and set a “neutral” rating on the stock in a report on Thursday, January 6th. Morgan Stanley assumed coverage on shares of Illumina in a research note on Thursday, January 6th. They issued an “equal weight” rating and a $425.00 target price for the company. Finally, Robert W. Baird decreased their price target on shares of Illumina from $493.00 to $437.00 and set a “neutral” rating for the company in a research note on Monday, November 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $443.69.

Shares of NASDAQ:ILMN opened at $405.14 on Friday. The company has a quick ratio of 2.24, a current ratio of 2.68 and a debt-to-equity ratio of 0.16. The stock’s 50 day moving average is $378.55 and its 200-day moving average is $428.48. Illumina, Inc. has a twelve month low of $341.03 and a twelve month high of $555.77. The firm has a market capitalization of $63.32 billion, a price-to-earnings ratio of 66.53, a PEG ratio of 3.11 and a beta of 0.90.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, November 4th. The life sciences company reported $1.45 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.21. Illumina had a net margin of 21.17% and a return on equity of 15.03%. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the firm posted $1.02 EPS. The firm’s quarterly revenue was up 39.3% compared to the same quarter last year. Equities research analysts anticipate that Illumina, Inc. will post 5.66 earnings per share for the current fiscal year.

In related news, SVP Susan H. Tousi sold 100 shares of the company’s stock in a transaction that occurred on Wednesday, December 8th. The shares were sold at an average price of $375.00, for a total value of $37,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Charles Dadswell sold 314 shares of the firm’s stock in a transaction dated Friday, October 22nd. The shares were sold at an average price of $411.00, for a total value of $129,054.00. The disclosure for this sale can be found here. Insiders have sold 12,189 shares of company stock valued at $5,024,576 in the last quarter. Company insiders own 0.23% of the company’s stock.

Illumina Company Profile

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Featured Story: What does an outperform rating mean?

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.